|
International Meeting on Cardiovascular Interventions Breaks Free From Conventional BMS vs. DES Talk
CATANIA™ Stent Has Leaders Enthusiastic About Solutions
Friday, July 11, 2008
The annual Southern Interventional Meeting (SIM), held in Catania, Italy June 25 – 28, 2008 was highlighted by an empowering presentation of intermediate results from the Assessment of the Latest Non-Thrombogenic Angioplasty (ATLANTA) First-In-Man clinical study for the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F (CeloNova BioSciences, Newnan, GA, USA). Participants in this specialized conference were a select group of world leaders in Interventional Cardiology. The audience was intrigued and enthusiastic about the results seen using the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F, some saying that CATANIA™ represents a true breakthrough for solving current risks associated with stenting.
The CATANIA™ Coronary Stent System with NanoThin Polyzene®-F is a new class of stent. The CAT™, as it is called, is not a bare metal stent because it has a nanothin layer of Polyzene®-F. It is not a drug-eluting stent and does not contain any cytostatic or cytotoxic drugs or additives. It allows for quick vessel healing, is anti-inflammatory, anti-thrombogenic, bacterial-resistant and helps to prevent tissue reactions that lead to restenosis. A well-designed, cobalt-chromium alloy stent with thin struts and a 40 nanometer-thin surface treatment of Polyzene®-F, the CAT™ has a 0% thrombosis rate in clinical studies performed to date.
The ATLANTA FIM is the first study of its kind to take evaluation and analysis of clinical results to the cellular level. An independent laboratory used a diagnostic test called Optical Coherence Tomography (OCT) to evaluate patient outcomes in a sampling of the study population. Results seen through OCT suggest that a Polyzene®-F surface promotes quick and complete vessel healing, reducing the risk of thrombosis. Therefore, the CAT™ stent does not require long-term dual-antiplatelet therapy.
The CAT™ features highly biostable Polyzene®-F, a proprietary surface technology from CeloNova BioSciences. Polyzene®- F is an ultrapure, inorganic polymer that bestows biocompatible, anti-thrombogenic, bacterial-resistant, and anti-inflammatory properties to any device or substrate it coats. The body ‘perceives’ the Polyzene®-F coated implant as being a natural, integral part of itself. With the CAT™, all of these features combine to create what some physicians call “the safest stent” on the market, making the CAT™ a viable solution to many risks associated with stenting.
About CeloNova BioSciences, Inc.
Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company’s proprietary materials, Polyzene®-F. Polyzene®-F is highly lubricious, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company’s current products include its Embozene™ Color-Advanced Microspheres and the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F. Other innovative devices are currently in the company’s developmental pipeline. For more information, please visit www.celonova.com.
###
< Back to main news page
|
